Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
SPECTRUM PHARMACEUTICALS INC (SPPI)
|
Add to portfolio |
|
|
|
| Price: |
$1.59
| | Metrics |
| OS: |
205.3
|
M
| |
-242
|
% ROE
|
| Market cap: |
$326
|
M
| |
-334
|
% ROIC
|
|
Net cash:
|
$27.3
|
M
| |
$0.13
|
per share
|
|
EV:
|
$299
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($63.3)
|
M
| |
|
|
|
EBIT
|
($63.5)
|
M
| |
|
|
| EPS |
($0.37)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 146.4 | 162.6 |
| Revenue growth | | | | | | -100.0% | -9.9% | -13.0% |
| Cost of goods sold | 1.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 35.8 | 66.0 |
| Gross profit | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 110.6 | 96.5 |
| Gross margin | 82.3% | | | | | | 75.5% | 59.4% |
| Selling, general and administrative | 38.8 | 60.4 | 60.4 | 61.4 | 62.7 | 64.8 | 88.4 | 88.1 |
| Research and development | 42.2 | 87.3 | 109.4 | 79.3 | 75.2 | 51.5 | 59.1 | 51.1 |
| EBITA | -72.7 | -147.7 | -169.7 | -140.7 | -137.8 | -116.3 | -36.9 | -4.3 |
| EBITA margin | -718.8% | | | | | | -25.2% | -2.6% |
| Amortization of intangibles | | | | | | | 25.9 | 38.3 |
| EBIT | -72.7 | -147.7 | -169.7 | -140.7 | -137.8 | -116.3 | -62.9 | -42.6 |
| EBIT margin | -718.8% | | | | | | -42.9% | -26.2% |
| Pre-tax income | -78.1 | -158.4 | -171.3 | -144.6 | -128.6 | -122.7 | -72.1 | -52.2 |
| Income taxes | 0.0 | 0.0 | -0.1 | -9.2 | -1.9 | 21.9 | 2.3 | 0.4 |
| Tax rate | | | 0.0% | 6.4% | 1.5% | | | |
| Net income | -75.4 | -158.6 | -171.3 | -144.6 | -128.6 | -122.7 | -72.1 | -52.6 |
| Net margin | -745.5% | | | | | | -49.2% | -32.4% |
| |
| Diluted EPS | ($0.43) | ($1.02) | ($1.38) | ($1.31) | ($1.24) | ($1.44) | ($0.99) | ($0.81) |
| Shares outstanding (diluted) | 183.2 | 154.9 | 124.4 | 110.6 | 103.3 | 85.1 | 72.8 | 64.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|